Table 1 Patient characteristics at the start of second-line chemotherapy.
From: Efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma
LCNEC | SCLC | P value | |
|---|---|---|---|
N | 39 | 431 | |
Median age (range) | 68 (55–83) | 70 (43–87) | 0.169 |
Sex, n (%) | |||
Female | 7 (17.9) | 73 (16.9) | 0.826 |
Male | 32 (82.1) | 358 (83.1) | |
Smoking status, n (%) | |||
Never | 1 (2.6) | 5 (1.2) | 0.407 |
Ever smoker | 38 (97.4) | 426 (98.8) | |
ECOG performance status, n (%) | |||
0 | 8 (20.5) | 107 (24.8) | 0.896 |
1 | 26 (66.7) | 268 (62.2) | |
2 | 5 (12.8) | 52 (12.1) | |
3 | 0 (0.0) | 3 (0.7) | |
4 | 0 (0.0) | 1 (0.2) | |
LCNEC | 19 | ||
pLCNEC | 20 | ||
Stage at initial diagnosis (8th TMN classification), n (%) | |||
1 | 4 (10.3) | 7 (1.6) | 0.012 |
2 | 2 (5.1) | 17 (3.9) | |
3 | 13 (33.3) | 117 (27.1) | |
4 | 20 (51.3) | 290 (67.3) | |
Treatment-free interval, n (%) | |||
> 90 days | 13 (33.3) | 178 (41.3) | 0.396 |
≤ 90 days | 26 (66.7) | 253 (58.7) | |
History of thoracic radiation therapy, n (%) | |||
No | 31 (79.5) | 343 (79.6) | 1.000 |
Yes | 8 (20.5) | 88 (20.4) | |
History of thoracic surgery, n (%) | |||
No | 30 (76.9) | 411 (95.4) | < 0.001 |
Yes | 9 (23.1) | 20 (4.6) | |
Complication of ILD, n (%) | |||
No | 37 (94.9) | 338 (78.4) | 0.012 |
Yes | 2 (5.1) | 93 (21.6) | |
CNS metastasis at the start of second-line chemotherapy, n (%) | |||
No | 23 (59.0) | 211 (49.0) | 0.395 |
Yes | 14 (35.9) | 173 (40.1) | |
Not evaluated | 2 (5.1) | 47 (10.9) | |
Distant metastasis at the start of second-line chemotherapy, n (%) | |||
No | 3 (7.7) | 53 (12.3) | 0.604 |
Yes | 36 (92.3) | 378 (87.7) | |
Median duration from the start of initial treatment to second-line chemotherapy (days) (range) | 194 (21–1633) | 199 (21–2373) | 0.783 |
First-line chemotherapy, n (%) | |||
CDDP/CBDCA + ETP | 20 (51.3) | 328 (76.1) | |
CDDP + CPT-11 | 12 (30.8) | 70 (16.2) | |
CBDCA + ETP + atezolizmab | 0 (0.0) | 11 (2.6) | |
CDDP/CBDCA + ETP + durvalumab | 0 (0.0) | 4 (0.9) | |
CBDCA + paclitaxel | 6 (15.4) | 0 (0.0) | |
CBDCA + S-1 | 1 (2.6) | 0 (0.0) | |
Investigation drugs | 0 (0.0) | 18 (4.2) | |
First-line chemotherapy response, n (%) | |||
CR | 2 (5.1) | 15 (3.5) | < 0.001 |
PR | 16 (41.0) | 365 (84.7) | |
SD | 11 (28.2) | 32 (7.4) | |
PD | 8 (20.5) | 12 (2.8) | |
Not evaluate | 2 (5.1) | 7 (1.6) | |
